Compass Pathways set to file psilocybin depression drug for approval imminently
The filing would put Compass in a tight race to win the first US approval of a psychedelic medicine, against a nonprofit competitor.
Read at BioSpace βFull coverage Β· 6 outlets
- BioSpace Β· lead
- STATSTAT+: Who will get the first psychedelic approved?
- Yahoo Finance1 Reason Compass Pathways Is Worth a Second Look This Month
- Psychedelic AlphaBreaking: FDA Awards Priority Review Vouchers to Otsuka, Compass, and Usona
- The MicrodoseScientists test if ketamine has antidepressant effects under anesthesia; France is the first to approve IV ketamine for severe suicidal crisis
- SeekingalphaCOMPASS Pathways rebounds on earnings after selloff driven by rivalβs NDA submission